



Liste des publications IUCT-O/CRCT

Avril 2023

Version du 02/05/2023

(IF 2021)

1. Adam, J., Le Stang, N., Uguen, A., Badoual, C., Chenard, M.-P., Lantuéjoul, S., Maran-Gonzalez, A., Robin, Y.-M., Rochaix, P., Sabourin, J.-C., Soubeyran, I., Sturm, N., Svrcek, M., Vincent-Salomon, A., Radosevic-Robin, N., Penault-Llorca, F., 2023. **Multicenter harmonization study of pan-Trk immunohistochemistry for the detection of NTRK3 fusions.** Mod Pathol 100192. <https://doi.org/10.1016/j.modpat.2023.100192> - *cat A* - IF : 8.209
2. Al Tabaa, Y., Casasnovas, O., Baillet, C., Bachy, E., Nicolas-Virelizier, E., Schiano, J.M., Bailly, C., Kanoun, S., Guidez, S., Gyan, E., Gressin, R., Morineau, N., Ysebaert, L., Le Gouill, S., Tilly, H., Houot, R., Morschhauser, F., Cartron, G., Herbaux, C., 2023. **Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group.** Blood Adv 2023009911. <https://doi.org/10.1182/bloodadvances.2023009911> - *cat B* - IF : 7.637
3. Araujo-Ayala, F., Dobaño-López, C., Valero, J.G., Nadeu, F., Gava, F., Faria, C., Norlund, M., Morin, R., Bernes-Lasserre, P., Serrat, N., Playa-Albinyana, H., Giménez, R., Campo, E., Lagarde, J.-M., López-Guillermo, A., Gine, E., Colomer, D., Bezombes, C. & Pérez-Galán, P., 2023. **A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses.** Leukemia. <https://doi.org/10.1038/s41375-023-01885-1> - *cat A* - IF : 12.883
4. Arrestier, R., Chaba, A., Mabrouki, A., Saccheri, C., Canet, E., Pineton de Chambrun, M., Stoclin, A., Picard, M., Wallet, F., Perier, F., Turpin, M., Argaud, L., Decavèle, M., Issa, N., Cadoz, C., Klouche, K., Cohen, J., Mokart, D., Grouille, J., Urbina, T., Hua, C., Chosidow, O., Mekontso-Dessap, A., Azoulay, E., de Prost, N., 2023. **Necrotizing soft tissue infections in critically ill neutropenic patients:**

a French multicentre retrospective cohort study. Ann Intensive Care 13, 34.
<https://doi.org/10.1186/s13613-023-01125-w> - *cat B - IF : 10.318*

5. Bahlis, N.J., Costa, L.J., Facon, T., Harousseau, J.-L., Manier, S., Perrot, A., Touzeau, C., Mohty, M., 2023. **Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH).** Clin Hematol Int. <https://doi.org/10.1007/s44228-023-00036-8> - *cat NC*

6. Barbey, O., Lulka, H., Hanoun, N., Belhadj-Tahar, H., Vernejoul, F., Cambois, G., Tiraby, M., Buscail, L., Gross, F. & Cordelier, P., 2023. **Preclinical development of non-viral gene therapy for patients with advanced pancreatic cancer.** Mol Ther Methods Clin Dev 29, 162–172.
<https://doi.org/10.1016/j.omtm.2023.03.005> - *cat C - IF : 5.849*

7. Baudou, E., Danna, J., Tallet, J., Pollidoro, L., Tensaouti, F., Bertozzi, A.-I., Pariente, J., Courbieres, N., Dufour, C., Grill, J., Chaix, Y., Laprie, A., 2023. **Impact of a pediatric posterior fossa tumor and its treatments on motor procedural learning.** Eur J Paediatr Neurol 44, 37–45.
<https://doi.org/10.1016/j.ejpn.2023.03.005> - *cat C - IF : 3.692*

8. Bouche, C., Quail, D.F., 2023. **Fueling the Tumor Microenvironment with Cancer-Associated Adipocytes.** Cancer Res 83, 1170–1172.
<https://doi.org/10.1158/0008-5472.CAN-23-0505> - *cat A - IF : 13.312*

9. Brahmi, M., Gaspar, N., Gantzer, J., Toulmonde, M., Boudou-Rouquette, P., Bompas, E., Firmin, N., Valentin, T., Cancel, M., Duffaud, F., Bertucci, F., Perrin, C., Dufresne, A., Marec-Bérard, P., Jean-Denis, M., Ray-Coquard, I., Le Loarer, F., Pierron, G., Tirode, F., Blay, J.-Y., Watson, S., 2023. **Patterns of care and outcome of CIC-rearranged sarcoma patients: A nationwide study of the French sarcoma group.** Cancer Med 12, 7801–7807.
<https://doi.org/10.1002/cam4.5539> - *cat C - IF : 4.711*

10. Cavillon, A., Porcher, R., Filleron, T., 2023. **Reply to Binghao Zhao, Ruidong Zhang, and Jiaming Wu’s Letter to the Editor re: Ana Cavillon, Damien Pouessel, Nadine Houédé, et al. Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials.** Eur Urol. In press. <https://doi.org/10.1016/j.eururo.2023.02.011>. Eur Urol S0302-2838(23)02775–6. <https://doi.org/10.1016/j.eururo.2023.04.016> - *cat A - IF : 24.267*

11. Corvest, V., Marec-Bérard, P., Lervat, C., Pacquement, H., Toulmonde, M., Gentet, J.-C., Laurence, V., Cleirec, M., Mansuy, L., Bompas, E., Castex, M.-P., Taque, S., Filhon, B., Tabone, M.-D., Verité, C., Entz-Werle, N., Saumet, L., Guimard, G., Pondrom, M., Chevreau, C., Flandrin, J., Duranteau, L., Rousset-Jablonski, C., Brugières, L., Jimenez, M., Le Deley, M.-C., Gaspar, N., Fresneau, B., 2023. **Late toxicity comparison of alkylating-based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro-EWING99-R1 in France.** Int J Cancer 152, 1659–1667. <https://doi.org/10.1002/ijc.34326> - *cat B - IF : 7.316*

12. de Masson, A., Beylot-Barry, M., Ram-Wolff, C., Mear, J.-B., Dalle, S., d’Incan, M., Ingen-Housz-Oro, S., Orvain, C., Abraham, J., Dereure, O., Charbonnier, A., Cornillon, J., Longvert, C., Barete, S., Boulinguez, S., Wierzbicka-Hainaut, E., Aubin, F., Rubio, M.-T., Bernard, M., Schmidt-Tanguy, A., Houot, R., Pham-Ledard, A., Michonneau, D., Brice, P., Labussière-Wallet, H., Bouaziz, J.-D., Grange, F., Moins-Teisserenc, H., Jondeau, K., Michel, L., Mourah, S., Battistella, M., Daguindau, E., Loschi, M., Picard, A., Franck, N., Maillard, N., Huynh, A., Nguyen, S., Marçais, A., Chaby, G., Ceballos, P., Le Corre, Y., Maury, S., Bay, J.-O., Adamski, H., Bachy, E., Forcade, E., Socié, G., Bagot, M., Chevret, S., Peffault de Latour, R., CUTALLO Investigators, Groupe Français d’Etude des Lymphomes Cutanés, Société Française de Greffe de Moëlle et Thérapie Cellulaire, 2023. **Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.** Lancet S0140-6736(23)00329-X. [https://doi.org/10.1016/S0140-6736\(23\)00329-X](https://doi.org/10.1016/S0140-6736(23)00329-X) – *cat A+ - IF : 202.731*

13. De Sousa Violante, M., Michel, V., Romero, K., Bonifait, L., Baugé, L., Perrin-Guyomard, A., Feurer, C., Radomski, N., Mallet, L., Mistou, M.-Y., Cadel-Six, S., 2023. **Tell me if you prefer bovine or poultry sectors and I’ll tell you who you are: Characterization of Salmonella enterica subsp. enterica serovar Mbandaka in France.** Front Microbiol 14, 1130891. <https://doi.org/10.3389/fmicb.2023.1130891> - *cat B - IF : 6.064*

14. Delaby, N., Barateau, A., Chiavassa, S., Biston, M.-C., Chartier, P., Graulières, E., Guinement, L., Huger, S., Lacornerie, T., Millardet-Martin, C., Sottiaux, A., Caron, J., Gensanne, D., Pointreau, Y., Coutte, A., Biau, J., Serre, A.-A., Castelli, J., Tomsej, M., Garcia, R., Khamphan, C., Badey, A., 2023. **Practical and technical key challenges in head and neck adaptive radiotherapy: The GORTEC point of view.** Phys Med 109, 102568. <https://doi.org/10.1016/j.ejmp.2023.102568> - *cat D - IF : 3.119*

15. Dubernet, A., Toulmonde, M., Colombat, M., Hartog, C., Riviere, E., 2023. **Insulin amyloidosis: A case report.** Front Med (Lausanne) 10, 1064832. <https://doi.org/10.3389/fmed.2023.1064832> - *cat C - IF : 5.058*
16. Dubucs, C., Aziza, J., Sartor, A., Heitz, F., Sevely, A., Sternberg, D., Jardel, C., Cavallé-Garrido, T., Albrecht, S., Bernard, C., De Bie, I., Chassaing, N., 2023. **Severe Antenatal Hypertrophic Cardiomyopathy Secondary to ACAD9-Related Mitochondrial Complex I Deficiency.** Mol Syndromol 14, 101–108. <https://doi.org/10.1159/000526022> - *cat E - IF : 1.494*
17. Dulucq, S., Rigal-Huguet, F., Nicolini, F.E., Cony-Makhoul, P., Escoffre-Barbe, M., Gardembas, M., Legros, L., Rousselot, P., Liu, J., Rea, D., De Mas, V., Hayette, S., Raynaud, S., Lacoste-Roussillon, C., Robbesyn, F., Klein, E., Morisset, S., Mahon, F.-X., Etienne, G., 2023. **Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study.** Br J Haematol. <https://doi.org/10.1111/bjh.18796> - *cat B - IF : 8.615*
18. Duployez, N., Vasseur, L., Kim, R., Largeaud, L., Passet, M., L'Haridon, A., Lemaire, P., Fenwarth, L., Geffroy, S., Helevaut, N., Celli-Lebras, K., Adès, L., Lebon, D., Berthon, C., Marceau-Renaut, A., Cheok, M., Lambert, J., Récher, C., Raffoux, E., Micol, J.-B., Pigneux, A., Gardin, C., Delabesse, E., Soulier, J., Hunault, M., Dombret, H., Itzykson, R., Clappier, E., Preudhomme, C., 2023. **UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia.** Leukemia. <https://doi.org/10.1038/s41375-023-01906-z> - *cat A - IF : 12.883*
19. Fattore, D., Potestio, L., Genco, L., Pages, C., Ortiz, A., Fabbrocini, G., Sibaud, V., 2022. **Autoimmune Skin Diseases and Immune Checkpoint Inhibitors.** Crit Rev Immunol 42, 11–22. <https://doi.org/10.1615/CritRevImmunol.2023047032> - *cat E - IF : 1.735*
20. Fourcade, C., Gomez-Brouchet, A., Bouige, A., Krin, G., Bicart-See, A., Marlin, P., Gautie, L., Giordano, G., Bonnet, E., 2023. **Can we rely on histopathological results for the diagnostic of prosthetic joint infection?** Infect Dis Now 104706. <https://doi.org/10.1016/j.idnow.2023.104706> - *cat C - IF : 5.965*
21. Frenel, J.-S., Lusque, A., Delaloge, S., Ferrero, J.-M., Bachelot, T., Desmoulins, I., Levy, C., Eymard, J.-C., Gonçalves, A., Patsouris, A., Reynier, M.A.M., Thery, M.J.-C., Petit, T., Cabel, L., Uwer, L., Debled, M., Chevrot, M., Mailliez, A., Jacot,

W., de La Motte Rouge, T., 2023. **Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation.** Br J Cancer. <https://doi.org/10.1038/s41416-023-02248-4> - *cat B - IF : 9.075*

22. Gronnier, C., Mariette, C., Lepage, C., Monterymard, C., Jary, M., Ferru, A., Baconnier, M., Adhoute, X., Tavan, D., Perrier, H., Guerin-Meyer, V., Lecaille, C., Bonichon-Lamichhane, N., Pillon, D., Cojocarasu, O., Egretieu, J., D'journo, X.B., Dahan, L., Locher, C., Texereau, P., Collet, D., Michel, P., Ben Abdelghani, M., Guimbaud, R., Muller, M., Bouché, O., Piessen, G., 2023. **Perioperative Cetuximab with Cisplatin and 5-Fluorouracil in Esogastric Adenocarcinoma: A Phase II Study.** Cancers (Basel) 15, 2188. <https://doi.org/10.3390/cancers15072188> - *cat B - IF : 6.575*

23. Guilleminault, L., Demoulin-Alexikova, S., de Gabory, L., Varannes, S.B.D., Brouquières, D., Balaguer, M., Chapron, A., Delyle, S.G., Poussel, M., Guibert, N., Reyckler, G., Trzepizur, W., Woissard, V., Crestani, S., 2023. **Guidelines for the management of chronic cough in adults. Endorsed by the French speaking society of respiratory diseases (Société de Pneumologie de Langue Française, SPLF), the Société Française d'Oto-Rhino-Laryngologie et de Chirurgie de la Face et du Cou (SFORL), the Société Française de Phoniatrie et de Laryngologie (SFPL), the Société Nationale Française de Gastro-entérologie (SNFGE).** Respir Med Res 83, 101011. <https://doi.org/10.1016/j.resmer.2023.101011> - *cat D - IF : 3.149*

24. Hartl, D., Godbert, Y., Carrat, X., Bardet, S., Lasne-Cardon, A., Vera, P., Ilies, E., Zerdoud, S., Sarini, J., Zalzal, M., La Manna, L., Schneegans, O., Kelly, A., Kauffmann, P., Rodien, P., Brunaud, L., Grunenwald, S., Housseau, E., Laghouati, S., Bouvet, N., Lecerf, E., Hadoux, J., Lamartina, L., Schlumberger, M., Borget, I., 2023. **ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial.** Trials 24, 298. <https://doi.org/10.1186/s13063-023-07294-0> - *cat E - IF : 1.676*

25. Hélias-Rodzewicz, Z., Donadieu, J., Terrones, N., Barkaoui, M.-A., Lambilliotte, A., Moshous, D., Thomas, C., Azarnoush, S., Pasquet, M., Mansuy, L., Aladjidi, N., Jeziorski, E., Marec-Berard, P., Gilibert-Yvert, M., Spiegel, A., Saultier, P., Pellier, I., Pagnier, A., Pertuisel, S., Poiree, M., Bodet, D., Millot, F., Isfan, F., Stephan, J.-L., Leruste, A., Rigaud, C., Filhon, B., Carausu, L., Reguerre, Y., Kieffer, I., Brichard, B., Ben Jannet, R., Bakari, M., Idbaih, A., Bodemer, C., Cohen-Aubart, F., Haroche, J., Tazi, A., Boudjemaa, S., Fraitag, S., Emile, J.-F.,

- Heritier, S., French Histiocytosis Study Group, 2023. **Molecular and clinicopathologic characterization of pediatric histiocytoses**. Am J Hematol. <https://doi.org/10.1002/ajh.26938> - cat A - IF : 13.265
26. Ingen-Housz-Oro, S., Milpied, B., Bensaid, B., Elshot, Y., Brügggen, M.C., Starace, M., Kaffenberger, B.H., Carrera, C., Pham-Ledard, A., Freites-Martinez, A., Sanchez-Pena, P., Lebrun-Vignes, B., French, L.E., Sibaud, V., 2023. **Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases**. Melanoma Res 33, 155–158. <https://doi.org/10.1097/CMR.0000000000000877> - cat C - IF : 3.199
27. Laloï, L., Billotey, N.C., Dumas, P.-Y., Paul, F., Villate, A., Simand, C., Fornecker, L., Puisset, F., Bertoli, S., Simonet, M.B., Laribi, K., Houyou, D., Santagostino, A., Michel, C., Guepin, G.R., Guerineau, E., Tabrizi, R., Hunault, M., Giltat, A., Kaphan, E., Bulaboï, C., Cartet, E., Rocher, C., Lachenal, F., Morisset, S., Récher, C., Pigneux, A., Belhabri, A., Michallet, M., Michallet, A.-S., 2023. **Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy**. Cancer Med 12, 7175–7181. <https://doi.org/10.1002/cam4.5459> - cat C - IF : 4.711
28. Largeot, A., Klapp, V., Viry, E., Gonder, S., Fernandez Botana, I., Blomme, A., Benzarti, M., Pierson, S., Duculty, C., Marttila, P., Wierz, M., Gargiulo, E., Pagano, G., An, N., El Hachem, N., Perez Hernandez, D., Chakraborty, S., Ysebaert, L., François, J.-H., Cortez Clemente, S.D., Berchem, G., Efremov, D.G., Dittmar, G., Szpakowska, M., Chevigne, A., Nazarov, P.V., Helleday, T., Close, P., Meiser, J., Stamatopoulos, B., Désaubry, L., Paggetti, J., Moussay, E., 2023. **Inhibition of MYC translation through targeting of the newly identified PHB-eIF4F complex as therapeutic strategy in CLL**. Blood blood.2022017839. <https://doi.org/10.1182/blood.2022017839> - cat A - IF : 25.476
29. Leboulleux, S., Do Cao, C., Zerdoud, S., Attard, M., Bournaud, C., Lacroix, L., Benisvy, D., Taïeb, D., Bardet, S., Terroir-Cassou-Mounat, M., Anizan, N., Bouvier-Morel, E., Lamartina, L., Lion, G., Betrian, S., Sajous, C., Schiazza, A., Garcia, M.-E., Ciappuccini, R., Schlumberger, M., Al Ghuzlan, A., Godbert, Y., Borget, I., 2023. **A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E Mutated Differentiated thyroid Cancer**. Clin Cancer Res CCR-23-0046. <https://doi.org/10.1158/1078-0432.CCR-23-0046> - cat A - IF : 13.801

30. Licaj, I., Coquan, E., Dabakuyo-Yonli, T.S., Dauchy, S., Vaz Luis, I., Charles, C., Lemogne, C., Tredan, O., Vanlemmens, L., Jouannaud, C., Levy, C., Rigal, O., Fournier, M., Petit, T., Dalenc, F., Rouanet, P., Lemonnier, J., Everhard, S., Cottu, P., Joly, F., 2023. **Baseline quality of life and chemotherapy toxicities in patients with early breast cancer.** *Cancer* 129, 1085–1095. <https://doi.org/10.1002/cncr.34643> - *cat B - IF : 6.924*
31. Lizard, G., Poirot, M., Iuliano, L., 2023. **European Network for Oxysterol Research (ENOR): 10th ENOR Symposium - Web Meeting.** *Steroids* 109242. <https://doi.org/10.1016/j.steroids.2023.109242> - *cat E - IF : 2.76*
32. Lu, X., Vano, Y., Helleux, A., Su, X., Lindner, V., Davidson, G., Mouawad, R., Spano, J.-P., Rouprêt, M., Elaidi, R., Compérat, E., Verkarre, V., Sun, C., Chevreau, C., Bennamoun, M., Lang, H., Tricard, T., Cheng, W., Xu, L., Davidson, I., Yan, F., Fridman, W.H., Sautes-Fridman, C., Oudard, S., Malouf, G.G., 2023. **An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas.** *Clin Cancer Res* 29, 1279–1291. <https://doi.org/10.1158/1078-0432.CCR-22-2133> - *cat A - IF : 13.801*
33. Marra, G., van Leenders, G.J.L.H., Zattoni, F., Kesch, C., Rajwa, P., Cornford, P., van der Kwast, T., van den Bergh, R.C.N., Briers, E., Van den Broeck, T., De Meerleer, G., De Santis, M., Eberli, D., Farolfi, A., Gillessen, S., Grivas, N., Grummet, J.P., Henry, A.M., Lardas, M., Lieu, M., Linares Espinós, E., Mason, M.D., O’Hanlon, S., van Oort, I.M., Oprea-Lager, D.E., Ploussard, G., Rouvière, O., Schoots, I.G., Stranne, J., Tilki, D., Wiegel, T., Willemse, P.-P.M., Mottet, N., Gandaglia, G., European Association of Urology Young Academic Urologists Prostate Cancer Working Group, the EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines Panel on Prostate Cancer, 2023. **Impact of Epithelial Histological Types, Subtypes, and Growth Patterns on Oncological Outcomes for Patients with Nonmetastatic Prostate Cancer Treated with Curative Intent: A Systematic Review.** *Eur Urol* S0302-2838(23)02654–4. <https://doi.org/10.1016/j.eururo.2023.03.014> - *cat A - IF : 24.267*
34. Mattei, P., Dghayem, D., Dupret-Bories, A., Sarini, J., Vairel, B., Rivière, L.-D., Vergez, S., Lusque, A., Chabrilac, E., 2023. **Should an elective contralateral neck dissection be performed in midline-reaching squamous cell carcinomas of the oral cavity and oropharynx?** *Eur J Surg Oncol* S0748-7983(23)00421–3. <https://doi.org/10.1016/j.ejso.2023.03.224> - *cat B - IF : 4.037*

35. Meyer, C., Larghero, P., Almeida Lopes, B., Burmeister, T., Gröger, D., Sutton, R., Venn, N.C., Cazzaniga, G., Corral Abascal, L., Tsaur, G., Fechina, L., Emerenciano, M., Pombo-de-Oliveira, M.S., Lund-Aho, T., Lundán, T., Montonen, M., Juvonen, V., Zuna, J., Trka, J., Ballerini, P., Lapillonne, H., Van der Velden, V.H.J., Sonneveld, E., Delabesse, E., de Matos, R.R.C., Silva, M.L.M., Bomken, S., Katsibardi, K., Keernik, M., Grardel, N., Mason, J., Price, R., Kim, J., Eckert, C., Lo Nigro, L., Bueno, C., Menendez, P., Zur Stadt, U., Gameiro, P., Sedék, L., Szczepański, T., Bidet, A., Marcu, V., Shichrur, K., Izraeli, S., Madsen, H.O., Schäfer, B.W., Kubetzko, S., Kim, R., Clappier, E., Trautmann, H., Brüggemann, M., Archer, P., Hancock, J., Alten, J., Möricke, A., Stanulla, M., Lentès, J., Bergmann, A.K., Strehl, S., Köhrer, S., Nebral, K., Dworzak, M.N., Haas, O.A., Arfeuille, C., Caye-Eude, A., Cavé, H., Marschalek, R., 2023. **The KMT2A recombinoe of acute leukemias in 2023.** Leukemia. <https://doi.org/10.1038/s41375-023-01877-1> - *cat A - IF : 12.883*
36. Michallet, A.-S., Letestu, R., Le Garff-Tavernier, M., Campos, L., Ticchioni, M., Dilhuydy, M.-S., Morisset, S., Rouille, V., Mahe, B., Laribi, K., Villemagne, B., Ferrant, E.F., Tournilhac, O., Delmer, A.J., Molina, L., Leblond, V., Tomowiak, C., De Guibert, S., Orsini Piocelle, F., Banos, A., Carassou, P., Cartron, G., Fornecker, L.-M., Ysebaert, L., Dartigeas, C., Truchan-Graczyk, M., Vilque, J.-P., Aurrant Schleinitz, T., Cymbalista, F., Leprêtre, S., Lévy, V., Nguyen-Khac, F., Feugier, P., 2023. **A fixed-duration, immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.** Blood Adv bloodadvances.2022009594. <https://doi.org/10.1182/bloodadvances.2022009594> - *cat B - IF : 7.637*
37. Mohty, M., Malard, F., Alaskar, A.S., Aljurf, M., Arat, M., Bader, P., Baron, F., Bazarbachi, A., Blaise, D., Brissot, E., Ciceri, F., Corbacioglu, S., Dalle, J.-H., Dignan, F., Huynh, A., Kenyon, M., Nagler, A., Pagliuca, A., Perić, Z., Richardson, P.G., Ruggeri, A., Ruutu, T., Yakoub-Agha, I., Duarte, R.F., Carreras, E., 2023. **Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT).** Bone Marrow Transplant. <https://doi.org/10.1038/s41409-023-01992-8> - *cat C - IF : 5.174*
38. Müller, S., Filali, L., Puissegur, M.-P., Valitutti, S., 2023. **Measuring CTL Lytic Granule Secretion and Target Cell Membrane Repair by Fluorescent Lipophilic Dye Uptake at the Lytic Synapse.** Methods Mol Biol 2654, 463–476. https://doi.org/10.1007/978-1-0716-3135-5_30 - *cat NC*

39. Othman, J., Meggendorfer, M., Tiacci, E., Thiede, C., Schlenk, R., Dillon, R., Stasik, S., Venanzi, A., Bertoli, S., Delabesse, E., Dumas, P.-Y., Pigneux, A., Bidet, A., Gilkes, A.F., Thomas, I., Voso, M.T., Rambaldi, A., Brunetti, L., Perriello, V.M., Andresen, V., Gjertsen, B.T., Martelli, M.P., Récher, C., Röllig, C., Bornhäuser, M., Serve, H., Müller-Tidow, C., Baldus, C.D., Haferlach, T., Russell, N., Falini, B., 2023. **Overlapping features of therapy-related and de novo NPM1-mutated AML.** Blood 141, 1846–1857. <https://doi.org/10.1182/blood.2022018108> - *cat A - IF : 25.476*

40. Renaudineau, Y., Bost, C., Abravanel, F., Izopet, J., Blancher, A., Congy, N., Treiner, E., Sailer, L., 2023. **Glucocorticoids selectively affect the memory T cell response to SARS-Cov2 spike in vaccinated and post-infected patients with systemic lupus erythematosus.** J Transl Autoimmun 6, 100200. <https://doi.org/10.1016/j.jtauto.2023.100200> - *cat NC*



41. Rieu, J.-B., Canali, A., Thene, E., Tavitian, S., Bertoli, S., 2023. **Acute promyelocytic leukaemia associated with atypical basophilia.** Br J Haematol. <https://doi.org/10.1111/bjh.18793> - *cat B - IF : 8.615*


42. Sabatier, M., Birsén, R., Lauture, L., Mouche, S., Angelino, P., Dehairs, J., Goupille, L., Boussaid, I., Heiblig, M., Boet, E., Sahal, A., Saland, E., Santos, J.C., Armengol, M., Fernandez-Serrano, M., Farge, T., Cognet, G., Simonetta, F., Pignon, C., Graffeuil, A., Mazzotti, C., Avet-Loiseau, H., Delos, O., Bertrand-Michel, J., Chedru, A., Dembitz, V., Gallipoli, P., Anstee, N.S., Loo, S., Wei, A.H., Carroll, M., Goubard, A., Castellano, R., Collette, Y., Vergez, F., Mansat-De Mas, V., Bertoli, S., Tavitian, S., Picard, M., Recher, C., Bourges-Abella, N., Granat, F., Kosmider, O., Sujobert, P., Colsch, B., Joffre, C., Stuani, L., Swinnen, J.V., Guillou, H., Roue, G., Hakim, N., Dejean, A.S., Tsantoulis, P., Larrue, C., Bouscary, D., Tamburini, J. & Sarry, J.-E., 2023. **C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia.** Cancer Discov CD-22-0411. <https://doi.org/10.1158/2159-8290.CD-22-0411> - *cat A - IF : 38.272*

43. Solomon, B.J., Bauer, T.M., Mok, T.S.K., Liu, G., Mazieres, J., de Marinis, F., Goto, Y., Kim, D.-W., Wu, Y.-L., Jassem, J., López, F.L., Soo, R.A., Shaw, A.T., Polli, A., Messina, R., Iadeluca, L., Toffalorio, F., Felip, E., 2023. **Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.** Lancet Respir Med 11, 354–366. [https://doi.org/10.1016/S2213-2600\(22\)00437-4](https://doi.org/10.1016/S2213-2600(22)00437-4) – *cat A – IF : 102.642*

44. Talbot, A., Bobin, A., Tabone, L., Lambert, J., Boccaccio, C., Deal, C., Petillon, M.-O., Allangba, O., Agape, P., Arnautou, P., Belkhir, R., Cailleres, S., Chaoui, D., Chrétien, M.-L., Decaux, O., Schulmann, S., Frenzel, L., Gastaud, L., Huart, A., Hulin, C., Karlin, L., Laribi, K., Le Calloch, R., Lenain, P., Macro, M., Manier, S., Montes, L., Moreau, S., Moreau, P., Morel, V., Norwood, J., Piocelle, F.O., Perrot, A., Pica, G.M., Rey, P., Schmitt, A., Stoppa, A.-M., Tiab, M., Touzeau, C., Vidal, V., Vignon, M., Vincent, L., Van De Wyngaert, Z., Zarnitsky, C., Kerbouche, N., Paka, P., Leleu, X., Arnulf, B., Avet-Loiseau, H., IFM: Intergroupe Francophone du Myélome, 2023. **Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: IFM 2020-04 study.** Haematologica. <https://doi.org/10.3324/haematol.2022.281772> - *cat A* - *IF : 11.047*
45. Tempero, M.A., Pelzer, U., O'Reilly, E.M., Winter, J., Oh, D.-Y., Li, C.-P., Tortora, G., Chang, H.-M., Lopez, C.D., Bekaii-Saab, T., Ko, A.H., Santoro, A., Park, J.O., Noel, M.S., Frassinetti, G.L., Shan, Y.-S., Dean, A., Riess, H., Van Cutsem, E., Berlin, J., Philip, P., Moore, M., Goldstein, D., Tabernero, J., Li, M., Ferrara, S., Le Bruchec, Y., Zhang, G., Lu, B., Biankin, A.V., Reni, M., AFACT Investigators [collab : Guimbaud, R.], 2023. **Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.** J Clin Oncol 41, 2007–2019. <https://doi.org/10.1200/JCO.22.01134> - *cat A* - *IF : 50.717*
46. Tensaouti, F., Desmoulin, F., Gilhodes, J., Roques, M., Ken, S., Lotterie, J.-A., Noël, G., Truc, G., Sunyach, M.-P., Charissoux, M., Magné, N., Lubrano, V., Péran, P., Cohen-Jonathan Moyal, E., Laprie, A., 2023. **Is pre-radiotherapy metabolic heterogeneity of glioblastoma predictive of progression-free survival?** Radiother Oncol 109665. <https://doi.org/10.1016/j.radonc.2023.109665> - *cat B* - *IF : 6.901*
47. Thibault, C., Fléchon, A., Albiges, L., Joly, C., Barthelemy, P., Gross-Goupil, M., Chevreau, C., Coquan, E., Rolland, F., Laguerre, B., Gravis, G., Pécuchet, N., Elaidi, R.-T., Timsit, M.-O., Brihoum, M., Auclin, E., de Reyniès, A., Allory, Y., Oudard, S., 2023. **Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24).** Eur J Cancer 186, 83–90. <https://doi.org/10.1016/j.ejca.2023.03.018> - *cat B* - *IF : 10.002*

48. Yafour, N., Couturier, M.-A., Borel, C., Charbonnier, A., Coman, T., Fayard, A., Masouridi-Levrat, S., Yakoub-Agha, I., Roy, J., 2023. [Second allogeneic (update). Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer S0007-4551(23)00149-2. <https://doi.org/10.1016/j.bulcan.2023.03.005> - cat E - IF : 1.318





IF 2021